From the genome to the drug: how the UAE bets on a vital chain led by artificial intelligence

Drug development does not start with the drug alone. Before a therapy reaches the patient, there are genetic samples, clinical data, labs, manufacturing facilities, and a network of researchers, regulators and investors. A new report linked to the Global Health Exhibition finds that the UAE is building the entire chain, placing artificial intelligence within a broader pathway that includes the genome, precision medicine and local manufacturing.

The report, prepared by the Global Health Exhibition in partnership with Frost & Sullivan, expects precision-medicine growth in the Middle East of between 10 % and 12 % over the next five to seven years. It does not present artificial intelligence as a standalone solution, but as part of a regional system that brings together next-generation therapies, AI-supported drug development, and local manufacturing capability.

Health data become a research infrastructure

In the UAE, the report links this shift to the Emirates Genome Program, which aims to collect one million genetic samples nationwide and to study the Emirati reference genome, analysing more than 50,000 samples. It says that this infrastructure supports disease prevention, precision therapies and health research. It also notes expectations that expanding patient databases locally could open opportunities for disease modelling and drug discovery over the next ten to fifteen years.

Here the practical value of artificial intelligence appears. According to Frost & Sullivan, more than 40 AI-discovered drugs have already entered clinical trials worldwide. These tools are used to identify new drug candidates more quickly, design more efficient clinical trials and improve manufacturing. However, the report places this capability within its conditions: possessing a model or algorithm is not enough if data, regulatory infrastructure, labs and the manufacturing pathway are missing.

Discovery is not the end of the road

The report records that the Insilico Medicine Centre in Abu Dhabi nominated in 2025 the first fully AI-discovered Emirati candidates for pre-clinical oncology and non-opioid pain, and that it completed discovery pathways in less than 12 months. It also notes a partnership announced in June 2026 between Abu Dhabi’s Health Authority and Boehringer Ingelheim, aimed at leveraging the growing genome infrastructure in Abu Dhabi to support precision-medicine research.

But the published piece emphasizes another knot: scaling scientific progress into widely available medicines requires cooperation among manufacturers, technology firms, investors, regulators, healthcare providers and commercial partners. Accordingly, the report links artificial intelligence with advanced manufacturing and logistical capabilities. It cites the launch of Mubadala Bio in 2025 to boost local manufacturing and pharmaceutical logistics in the UAE, and also mentions a Lifera agreement with Novo Nordisk to explore local production of advanced diabetes and obesity treatments in Saudi Arabia.

The region’s bet is local capability, not building others’ tools

For health and tech teams in the Gulf, Egypt and the Levant, the point is that the work required goes beyond purchasing analytical tools. The growth of genomic and patient databases raises the value of health-data management, clinical-trial, compliance and manufacturing skills, as well as data science. Building disease and therapy models that reflect the characteristics of regional populations is what distinguishes local research capacity from merely using technologies developed elsewhere.

The numbers appear large, but the more cautious message is the most important: artificial intelligence speeds up some stages of drug development, but does not eliminate the rest of the chain. The report tracks investments and infrastructure under construction, and forecasts growth, yet it does not equate expectation with a guaranteed outcome. The bet’s success hinges on linking data, research, regulation and production in a single system capable of turning discovery into an available therapy.